Skip to main content
TipRanks
Go Ultimate75% OFF

Top Page

NVOH

Novo Nordisk A/S (B Shares) ADRhedged (NVOH)

Rating:69Neutral
Price Target:$24.50â–²(2.93% Upside)

NVOH’s rating suggests it is a solid but not perfect way to gain exposure to Novo Nordisk, with overall quality supported by its main holding. The fund is heavily concentrated in NVO, whose strong financial performance, long-term growth focus, and attractive dividend help drive the rating, but bearish technical signals and recent challenges like market share loss and restructuring keep the fund from scoring higher. The key risk for investors is this very high concentration in a single company, which means the ETF’s fortunes are closely tied to Novo Nordisk’s future performance.

Positive Factors
Focused Exposure to a Leading CompanyThe ETF is heavily invested in Novo Nordisk, a major global healthcare company with a strong long-term business profile.
Health Care Sector FocusConcentration in the health care sector provides exposure to a defensive industry that often holds up better during economic slowdowns.
Low Expense RatioThe fund’s relatively low ongoing fee means less of your investment is eaten up by costs over time.
Negative Factors
Extreme Single-Stock ConcentrationWith almost all assets in one company, investors face high risk if Novo Nordisk’s share price or business weakens.
Recent Weak PerformanceThe ETF has shown weak year-to-date and three-month performance, reflecting recent struggles in its main holding.
Limited Diversification by Sector and RegionHeavy exposure to U.S-listed health care and a single stock means the fund offers little protection if that sector or company faces problems.

NVOH vs. SPDR S&P 500 ETF (SPY)

-30%-20%-10%0%10%20%30%40%SPY+14.55%NVOH-3.82%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
AUM
3.94M
Region
Europe
Expense Ratio
0.19%
Beta
0.95
Issuer
ADRhedged
Inception Date
Jan 07, 2025
Dividend Yield
6.55%
Asset Class
Equity
Index Tracked
No Underlying Index

NVOH Summary

NVOH is an ETF that focuses on one main company: Novo Nordisk, a global leader in diabetes and obesity treatments. It doesn’t track a broad index, but instead gives targeted exposure to the health care and pharmaceuticals theme, mainly through Novo Nordisk shares. Investors might consider NVOH if they believe in the long-term growth of treatments for chronic diseases and want a simple way to invest in a major player in that space, with some protection against currency swings. A key risk is that the fund is heavily concentrated in a single company, so its value can rise or fall sharply based on Novo Nordisk’s performance.

How much will it cost me?

This ETF has an expense ratio of 0.19%, which means you’ll pay about $1.90 per year for every $1,000 invested. That’s slightly higher than the cheapest broad-market index ETFs, mainly because this fund is very specialized and focused on a single company and currency hedging strategy.

What would affect this ETF?

Future performance of this Denmark-focused health care ETF will largely depend on how well Novo Nordisk continues to grow its diabetes and obesity treatments, benefits from new drug approvals, and navigates global demand for pharmaceuticals. On the downside, tighter drug pricing rules, competition from other pharmaceutical companies, changes in health care regulations, or broader economic and interest rate shifts that reduce investor appetite for European health care stocks could hurt returns, and the heavy concentration in a single company increases the impact of any negative news about Novo Nordisk.

NVOH Top 10 Holdings

This ETF is essentially a one-stock story: Novo Nordisk dominates the portfolio and sets the tone for performance. After a strong recent pop, the stock’s longer-term trend has been more mixed, with earlier weakness still weighing on year-to-date results. That means when Novo Nordisk is rising on optimism around its diabetes and obesity drugs, the fund looks strong; when the stock stumbles on technical or competitive concerns, the ETF feels it directly. Sector-wise, it’s a pure play on European pharmaceuticals, with all roads leading back to Denmark.

NVOH top ten holdings
NameCompany NameWeight %Market ValueMarket CapYearly GainOverall Rating
NVONVONovo Nordisk92.76%$3.73M$182.02B-15.32%73Outperform

NVOH Technical Analysis

Technical Analysis SentimentPositive
Last Price23.80

Price Trends

50DMA22.41Positive
100DMA24.19Negative
200DMA23.28Positive

Market Momentum

MACD0.32Negative
RSI61.85Neutral
STOCH39.19Neutral

Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For NVOH, the sentiment is Positive. The current price of 23.80 is above the 20-day moving average (MA) of 22.60, above the 50-day MA of 22.41, and above the 200-day MA of 23.28, indicating a bullish trend. The MACD of 0.32 indicates Negative momentum. The RSI at 61.85 is Neutral, neither overbought nor oversold. The STOCH value of 39.19 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for NVOH.

NVOH Peer Comparison

Comparison Results

NVOH against its peer funds
NamePricePrice TargetAUMExpense RatioOverall Rating
NVOHNVOH$23.80$24.50(2.93% Upside)$3.94M0.19%69Neutral
ASMHASMH$10.77$17.56(63.03% Upside)$4.61M0.19%76Outperform
ARMHARMH$8.27$12.42(50.16% Upside)$4.23M0.19%67Neutral
HSBHHSBH$101.18―$3.02M0.19%76Outperform
BPHBPH$73.43$85.44(16.35% Upside)$2.18M0.19%65Neutral
GSKHGSKH$72.64$82.99(14.26% Upside)$719.07K0.19%75Outperform

Performance Comparison

0%50%100%150%200%NVOHASMHARMHHSBHBPHGSKHDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
NVOH and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
NVOHNovo Nordisk A/S (B Shares) ADRhedged23.80-1.39-5.53%
ASMHASML Holding NV ADRhedged10.773.9257.21%
ARMHArm Holdings PLC ADRhedged8.272.2437.20%
HSBHHSBC Holdings plc ADRhedged101.1822.7929.07%
BPHBP p.l.c. ADRhedged73.4316.3428.62%
GSKHGSK plc ADRhedged72.646.039.05%
Glossary
BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer

This AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.